Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
13 Nov, 26
AHA 2026
The sessions presented at AHA 2026, underscore the importance of secondary prevention in MI patients and focus on the benefits of beta-blocker treatment and reperfusion treatment in these patients.
12 Nov, 26AHA 2026
The AHA highlights focus on risk-guided intensive BP control, novel aldosterone synthase inhibitors, GLP-1RA–mediated BP reduction, digital BP management, and real-world combination therapy outcomes.
9 Nov, 26BMC Infect. Dis.
- Meta-analysis of 99 cohort studies found poor glycemic control significantly reduced treatment success (adjusted OR 0.22) & sputum conversion (adjusted OR 0.28).
- Poor glycemic control was associated with lower lesion resolution and cavity closure.
- Recurrence risk was nearly 5-fold higher with poor glycemic control; no significant differences were observed between FBG and HbA1c for short-term outcomes.
6 Nov, 26EP Europace.
- Among 2,712 Swiss-AF participants (mean age 73 yrs; 30.8% female), MRI-detected brain infarcts increased from 22.8% (AF-/HF-) to 44.6% (AF+/HF+), while white matter hyperintensities (WMH) increased from 43.2% to 65.6%
- AF & HF were independently associated with brain infarcts (AF: OR 1.78; HF: OR 1.32; both p<0.001) & WMH (AF: OR 1.71; HF: OR 1.45; both p<0.001), with no significant AF-HF interaction.
5 Nov, 26Diabetes Obes Metab.
- In a cohort of obesity-medication eligible adults without diabetes, 12 mo of persistent tirzepatide treatment produced clinically meaningful weight loss in both GLP-1 RA–naïve & experienced patients
- Mean weight reduction was 19.3% in GLP-1 RA–naïve patients & 13.1% in GLP-1 RA–experienced patients
- >85% had ≥1 obesity-related comorbidity at baseline, supporting effectiveness comparable to clinical trial outcomes.
3 Nov, 26Diabetic Med.
- This updated meta-analysis (25 studies; n=7,379) showed that preventive interventions initiated within 5 yrs after a GDM pregnancy reduced T2DM risk by 15% (RR 0.85; 95% CrI 0.69-1.04) & T2DM hazard by 32% (HR 0.68; 95% CrI 0.40-1.07), with high posterior probabilities (95%-96%)
- Improvements were also seen in FPG, BMI, HOMA-IR, & total cholesterol.
Featured
12 Nov, 26
26 Oct, 26
26 Oct, 26
